Real-world GLP-1 RA therapy in type 2 diabetes: A long-term effectiveness observational study.

Endocrinol Diabetes Metab · 2019 · PMC6354754 · PMID 30815578

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

No differences were seen for different drugs in terms of HbA1c reduction, although exenatide twice daily and lixisenatide showed a trend for a lower fasting plasma glucose reduction as compared to liraglutide and weekly‐based GLP‐1 RAs.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.